Cas:924871-61-4 3-Bromo-8-(phenylsulfonyl)-1-oxa-8-azaspiro[4.5]decane manufacturer & supplier

Chemical Name:3-Bromo-8-(phenylsulfonyl)-1-oxa-8-azaspiro[4.5]decane

CAS.NO:924871-61-4

Synonyms:3-Bromo-8-(phenylsulfonyl)-1-oxa-8-azaspiro[4.5]decane

Molecular Formula:C₁₄H₁₈BrNO₃S

Molecular Weight:360.26700

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:485.783ºC at 760 mmHg

Density:1.563g/cm3

Index of Refraction:1.629

PSA:54.99000

Exact Mass:359.01900

LogP:3.41240

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-Bromo-8-(phenylsulfonyl)-1-oxa-8-azaspiro[4.5]decane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Bromo-8-(phenylsulfonyl)-1-oxa-8-azaspiro[4.5]decane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Bromo-8-(phenylsulfonyl)-1-oxa-8-azaspiro[4.5]decane Use and application,3-Bromo-8-(phenylsulfonyl)-1-oxa-8-azaspiro[4.5]decane technical grade,usp/ep/jp grade.

Related News: After this long manufacturing process, it is purified until it reaches a very high degree of purity and finally becomes an API. 3-Bromo-8-(phenylsulfonyl)-1-oxa-8-azaspiro[4.5]decane manufacturer In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday. 3-Bromo-8-(phenylsulfonyl)-1-oxa-8-azaspiro[4.5]decane supplier In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday. 3-Bromo-8-(phenylsulfonyl)-1-oxa-8-azaspiro[4.5]decane vendor At present, Teva can produce more than 300 generic drugs, and the API department has approximately 650 authorized patents and patent applications worldwide. It is also the generic drug company with the most challenges in patenting ParagraphIV in the world. 3-Bromo-8-(phenylsulfonyl)-1-oxa-8-azaspiro[4.5]decane factory In recent years, China’s bulk drug companies have gradually completed the upgrade of the product structure of bulk raw materials to specialty raw materials and intermediates. The industry’s leading companies have further developed the research and development layout of high-barrier generic pharmaceutical raw materials with multiple patents that have not yet expired.